Continuous glucose monitoring (Dexcom g6) in people with diabetes after kidney transplantation.

Ren Fail

Department of Nephrology, Dialysis and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.

Published: December 2024

AI Article Synopsis

  • * Nine participants (mostly women with median age 57) were monitored over 30 days using the Dexcom G6 CGM system after kidney transplantation, revealing that time in the healthy glucose range was above 70%.
  • * While the CGM use didn't change HbA1c levels or overall quality of life perception, it did enhance health quality perception for participants, indicating a potential benefit that warrants further research.

Article Abstract

Objectives: Use of continuous glucose monitoring-CGM in patients on kidney replacement therapy including kidney transplant recipients, may improve glycemic control and detection of hypoglycemia. However, studies in this population in particular in kidney transplant recipients are very limited.

Methods: The study aimed to evaluate glycemic profiles using the Dexcom G6 CGM system for 30 d a personal smartphone in people with diabetes after kidney transplantation and to assess the impact of monthly use of the CGM system on glycemic control and quality of life in this group.

Results: Over 8 months, 9 people after kidney transplantation were included in the study (7 women, median age 57 years), 8 people with new-onset diabetes after transplantation (NODAT), and 1 person with diabetes mellitus type 1. The time since kidney transplantation in each of the study participants was less than 2 years. In 7 people with NODAT, the time in range was above 70%. In all study participants, hyperglycemia was observed mainly in the afternoon (2-6 pm). In some patients, pressure-induced sensor attenuations (PISAs) were noted. There was no effect of the use of Dexcom G6 on the HbA1c value. There was no impact of the use of the Dexcom G6 system on the perception of overall quality of life, but monthly use had a positive impact on the perception of the quality of health.

Conclusions: CGM systems seem to be a promising method for assessing glycemic control in people with diabetes after kidney transplantation. More extensive research is needed to assess safety and usefulness in everyday practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485880PMC
http://dx.doi.org/10.1080/0886022X.2024.2413007DOI Listing

Publication Analysis

Top Keywords

kidney transplantation
20
people diabetes
12
diabetes kidney
12
glycemic control
12
continuous glucose
8
kidney
8
kidney transplant
8
transplant recipients
8
cgm system
8
quality life
8

Similar Publications

The mechanism(s) underlying gut microbial metabolite (GMM) contribution towards alcohol-mediated cardiovascular disease (CVD) is unknown. Herein we observe elevation in circulating phenylacetylglutamine (PAGln), a known CVD-associated GMM, in individuals living with alcohol use disorder. In a male murine binge-on-chronic alcohol model, we confirm gut microbial reorganization, elevation in PAGln levels, and the presence of cardiovascular pathophysiology.

View Article and Find Full Text PDF

Introduction: End-stage kidney disease patients face a critical decision regarding kidney replacement therapy options, which include kidney transplantation, hemodialysis, or peritoneal dialysis (PD). This study aims to evaluate the impact of nurse-led education (NE) alone vs. NE combined with peer support on the patients' decision over PD treatment in chronic kidney disease patients.

View Article and Find Full Text PDF

Background: Enhanced recovery after surgery (ERAS) protocols have gained widespread acceptance as a means to enhance surgical outcomes. However, the intricate care required for kidney transplant recipients has not yet led to the establishment of a universally recognized and dependable ERAS protocol for kidney transplantation.

Objective: We devised a customized ERAS protocol to determine its effectiveness in improving surgical and postoperative outcomes among kidney transplant recipients.

View Article and Find Full Text PDF

Purpose: This study aimed to assess whether kidney stone burden and risk factors at the time of kidney donor evaluation were associated with a symptomatic stone event post-donor evaluation.

Methods: We identified adults evaluated at Mayo Clinic (two sites) (2000-2011) for living kidney donation and had either a personal history or radiological evidence of kidney stone disease. We analyzed demographics, stone risk factors, stone number/size, and the committee's donation decision and reasons.

View Article and Find Full Text PDF

Simultaneous pancreas-kidney (SPK) transplantation is a recognized treatment for patients with insulin-dependent diabetes and advanced chronic kidney disease or end-stage renal disease (ESRD), offering significant survival benefits. However, it is associated with a higher risk of venous thrombosis, which can jeopardize the survival of the pancreaticoduodenal graft. This case report describes a patient with type 2 diabetes, hypertension, and ESRD who developed acute, occlusive deep vein thrombosis (DVT) involving the right common femoral, profunda femoral, and greater saphenous veins on postoperative day 1 (POD1) following a deceased donor SPK transplant, despite systemic prophylactic anticoagulation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!